Stathmin 2 is a potential treatment target for TDP-43 proteinopathy in amyotrophic lateral sclerosis.

Liu, Yunqing; Yan, Dejun; Yang, Lin; Chen, Xian; Hu, Chun; Chen, Meilan

Liu, Yunqing; Yan, Dejun; Yang, Lin; Chen, Xian; Hu, Chun; Chen, Meilan.

Afiliação

Liu Y; Key Laboratory of Brain, Cognition and Education Sciences, South China Normal University, Ministry of Education, Guangzhou, China.
Yan D; Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, 510631, China.
Yang L; Key Laboratory of Brain, Cognition and Education Sciences, South China Normal University, Ministry of Education, Guangzhou, China.
Chen X; Institute for Brain Research and Rehabilitation, South China Normal University, Guangzhou, 510631, China.
Hu C; Department of Anesthesiology, the Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China.
Chen M; Rehabilitation Medicine Institute of Panyu District, Guangzhou, 511499, China.

Transl Neurodegener ; 13(1): 20, 2024 Apr 11.

Article em En | MEDLINE | ID: mdl-38600555

Assuntos

Esclerose Lateral Amiotrófica; Estatmina; Proteinopatias TDP-43; Humanos; Esclerose Lateral Amiotrófica/complicações; Proteínas de Ligação a DNA/genética; Estatmina/antagonistas & inibidores; Proteinopatias TDP-43/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estatmina / Proteinopatias TDP-43 / Esclerose Lateral Amiotrófica Limite: Humans Idioma: En Revista: Transl Neurodegener / Translational neurodegeneration Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google